லேபராஸ்கோபிக் ப்ரொஸீஜர்ஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from லேபராஸ்கோபிக் ப்ரொஸீஜர்ஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In லேபராஸ்கோபிக் ப்ரொஸீஜர்ஸ் Today - Breaking & Trending Today

The Worldwide Urology Devices Industry is Expected to Reach $46 Billion by 2026 at a CAGR of 4.1% from 2021

Share this article
Share this article
ResearchAndMarkets.com s offering.
The global urology devices market is projected to reach USD 46,408.2 million by 2026 from USD 38,005.6 million in 2021, at a CAGR of 4.1%.
Market growth is driven by factors such as the growing number of hospitals and investments in endoscopy and laparoscopy facilities, rising incidence and prevalence of urological conditions, and growing preference for minimally invasive procedures. On the other hand, the high degree of market consolidation is expected to limit market growth to a certain extent in the coming years.
The consumables & accessories segment accounted for the highest growth rate in the urology devices market, by product, during the forecast period ....

United States , South Korea , Karl Storz , B Braun Melsungen , Richard Wolf Gmb , Dornier Medtech , Laura Wood , Boston Scientific Corporation , Company Evaluation Quadrant , Dialysis Centers , Ribbel International , Dynamic Companies , Baxter International Inc , Teleflex Incorporated , Stryker Corporation , Fresenius Medical Care Ag Co , Progressive Companies , Porter Five Forces Analysis , Jm Urinary Catheters , Office Hours Call , Research Methodology , Nikkiso Co , Responsive Companies , Company Profiles , E St Office Hours Call , Dialysis Center ,

TransEnterix Has A Compelling Case To Be The Next Intuitive Surgical

Medical devices company, TransEnterix (NYSEARCA:TRXC) is another small-cap growth stock that has sprung back to life in 2020. TRXC stock is up a whopping 1322% in the past six months. The company’s robotics platform will likely get significant traction this year, as regulatory approvals will support growth opportunities. The goal is for its “Senhance” robotics technology to gain widespread clinical adoption in the laparoscopic field. A few risks remain, though, and its inflated price limits TRXC stock’s attractiveness. Source: Shutterstock TransEnterix’s Senhance platform essentially reduces variability in surgical procedures and thus improves patient outcomes for laparoscopic procedures. The platform’s initial sales were encouraging but quickly dropped off, as it failed to meet physician expectations. However, the company has worked incredibly hard to fix its teething issues and invested in extensors such as its Intelligent Surgical Unit. FDA ....

Intuitive Surgical , Laparoscopic Procedures , Surgical Procedures , Trxc Stock , Robotics Technology , Medical Devices Company , Surgical Robotics , Platform Development , உள்ளுணர்வு அறுவை சிகிச்சை , லேபராஸ்கோபிக் ப்ரொஸீஜர்ஸ் , அறுவை சிகிச்சை ப்ரொஸீஜர்ஸ் , ரோபாட்டிக்ஸ் தொழில்நுட்பம் , மருத்துவ சாதனங்கள் நிறுவனம் , அறுவை சிகிச்சை ரோபாட்டிக்ஸ் , நடைமேடை வளர்ச்சி ,